Tag Archives: Immunotherapy

Immunotherapy and Its Use in Stage 2 and 3 Cancers

There is New Hope for Cancer Patients. Don't Give up!
There is New Hope for Cancer Patients. Don’t Give up!

Immunotherapy drugs have become a valuable weapon in the fight against metastatic cancer, also known as Stage 4. Researchers are discovering that immunotherapy for cancer treatment can also have positive results when used during earlier stages of the disease.

Immunotherapy and Early-Stage Cancer

At the recent European Society for Medical Oncology (ESMO) congress in Madrid, AstraZeneca presented successful trial results for its immuno-oncology drug Imfinzi in treating mid-stage lung cancer. AstraZeneca is considered a latecomer to the I-O field as compared to established companies such as Merck and Bristol-Meyers Squibb.

For their part, Bristol-Meyers produced evidence regarding Opdivo, the company’s widely used late-stage I-O drug. Opdivo has been shown to prevent relapses in melanoma patients when administered immediately post-surgery.

Supplementing Surgery with Immunotherapy

This method of following surgery with cancer treatment is referred to as adjuvant therapy. With the success of Opdivo, a number of trials are being conducted on adjuvant therapy using I-O drugs with a range of cancer types. Some trials are even focusing on neoadjuvant, or pre-surgery, treatment for breast, neck and head cancers.

What’s Next?

If the trend of early-stage immunotherapy treatment continues, early detection becomes even more important than ever. According to Pascal Soriot, CEO of AstraZeneca, effective early treatment is a powerful incentive for increased use of screening methods.

Non-Toxic Immunotherapy Programs from Issels®

Our cancer vaccines and other non-toxic, personally tailored immunotherapy treatment programs have resulted in long-term remission for patients with all types of therapy-resistant cancers. Contact us for more information about Issels®, the leader in immunotherapy for cancer treatment.

What Makes the Issels Immunotherapy Approach So Different?

Each Person is Different, and as a Result, so is Every Treatment Plan!
Each Person is Different, and as a Result, so is Every Treatment Plan!

Choosing a cancer treatment program can be the most important decision you’ll ever face. What makes the Issels® immunotherapy for cancer approach so different from traditional forms of cancer treatment?

Issels® Treatment Programs Are Individually Developed

Regardless of the type of cancer, each patient’s experience is unique. Our treatment programs are personally tailored to address a patient’s specific needs.

Issels® Therapies Are Created from a Patient’s Own Immune Cells

Issels® immunotherapy protocols boost your body’s immune response to use the power of your own natural defense mechanisms.

Issels® Immunotherapy Has No Adverse Side Effects

Immunotherapy is non-toxic and has less risk of side effects than traditional cancer treatments such as chemotherapy and radiation. Our immunotherapy programs should also be distinguished from pharmaceutically-developed immunotherapy drugs, which can trigger serious negative reactions.

Issels® Immunotherapy Programs Are Comprehensive

Focusing cancer treatment on one form can limit its impact on the disease. Our immunotherapy programs integrate a number of complementary elements that work together for greater effectiveness.

Issels® Treatment Programs Focus on Cancer and Its Environment

Destroying cancer cells is only part of the process. Our immunotherapy for cancer is also directed at altering the internal environment that promotes tumor growth.

Issels® Immunotherapy Is Not a Trial

Patients who participate in clinical trials may end up receiving a placebo. Our cancer vaccines and gene-targeted therapies have stood the test of time.

Experience the Issels® Difference

Want to learn more? Visit our website to read and hear testimonials from patients who have achieved years and decades of recurrence-free remission thanks to our Issels® immunotherapy for cancer programs.

What’s Happening in Colorectal Cancer Research?

 

Cancer Research is Making Progress Every Day. Here is the Latest for Colorectal Cancer.
Cancer Research is Making Progress Every Day. Here is the Latest for Colorectal Cancer.

Colorectal cancer is the third most common cancer diagnosed in the United States, but there are currently more than one million survivors in the country. The National Foundation for Cancer Research has some information you should know about this preventable disease.

Rates and Risks of Colorectal Cancer

• Overall risks of developing colorectal cancer are marginally higher for men. Approximately one in 21 is diagnosed with the disease, while the numbers for women are one in 23.

• Health factors that increase the risk of colorectal cancer include inflammatory bowel disorders, family history and genetics, and personal history of polyps or another form of cancer.

• Poor lifestyle choices such as smoking, obesity and high-fat diets, heavy alcohol use and physical inactivity also contribute to colorectal cancer risk.

Regular screenings can help prevent colorectal cancer.

Colorectal Cancer Research in the News

Genomics and immunotherapy for cancer are the main focus points of today’s colorectal cancer research.

• Dr. Wei Zhang and his NFCR-funded team are continuing their promising studies into biomarkers and their use in improving colorectal cancer prognosis and predicting responses to treatment.

• NFCR has also supported the work of Dr. Yung-Chi Cheng, who is on the cusp of producing one of the first FDA-approved oral herbal immunotherapies for cancer. When applied in combination with chemotherapy, PH906 has been found to ease gastrointestinal side effects that accompany treatment for colon and rectal cancers.

Personally Developed Immunotherapy for Cancer at Issels®

Our integrative, non-toxic cancer treatment programs are powerful and effective, but they avoid the often painful side effects of traditional treatments. Contact us for more information.

New Cancer Treatment Targets Protein Found in Tumors

Links to Cancer are Being Identified Everyday! There is Hope.
Links to Cancer are Being Identified Everyday! There is Hope.

Immunotherapy continues to be a major focus in cancer treatment research. Scientists in the United Kingdom recently began early-phase clinical trials of an experimental drug that targets a protein found in many solid tumors.

Using the Immune System to Attack Cancer Cells

Cancer Research UK and Biotecnol Limited are collaborating on development of a first-in-class Fdrug known as Tb535H. Arising from Trisoma®, Biotecnol’s antibody development platform, the drug targets the 5T4/WAIF1 antigen that is believed to contribute to the spread of cancer cells.

As with most immunotherapy treatments, Tb535H works by harnessing the immune system’s T cells and directing them to attack and kill cancer cells. Biotecnol has been instrumental in partnering with top cancer institutions to develop promising immune-oncology therapies.

Targeted Cancer Treatment

The discovery of the WAIF1 antigen also occurred as a result of studies at Cancer Research UK’s Manchester Institute. While it may ultimately be a target for a number of cancer types, current testing will be limited to cancers with low survival rates, including mesothelioma and small-cell lung carcinoma.

Dr. Nigel Blackburn, director of drug development for Cancer Research UK, acknowledged that the partnership with Biotecnol will accelerate the path of bringing Tb535H to cancer patients. Blackburn also stressed the need for more effective treatment for lung cancer, the cause of 20 percent of cancer deaths in the UK.

Issels® Offers State-of-the-Art Immunotherapy Programs

While immunotherapy is a hot buzzword in cancer treatment today, we have been using non-toxic integrative programs for decades. Contact us to read and hear testimonials from patients with all forms of cancer who have received successful treatment at Issels®.

Tumor Heterogeneity: Why Some Tumors Metastasize or are Drug Resistant

Each Body Is Unique, and So Is Curing Each Cancerous Tumor.
Each Body Is Unique, and So Is Curing Each Cancerous Tumor.

For decades, scientists have tried to uncover the mysteries behind the complex behaviors of cancer cells. Thanks to gene sequencing and other molecular diagnosis tools, they are beginning to understand the process behind metastasis and drug resistance.

Solving the Puzzles of Metastasis and Drug Resistance

Cancer treatment is sometimes hampered by two significant problems:

Metastasis, or stage IV cancer, occurs when cancer cells migrate from the original site to other parts of the body. Surgery is no longer an option at stage IV, which significantly reduces survival rates.

• Drug resistance sets in when treatment reaches a point where cancer cells are no longer vulnerable to attack and they resume spreading.

Scientists have discovered that cancer cells can vary greatly between the original site and metastatic site, and even within a single tumor. This characteristic is referred to as tumor heterogeneity.

How Does Tumor Heterogeneity Affect Cancer Treatment?

Research has uncovered significant evidence demonstrating that cancer cells continue to evolve.

Gene mutations can create a subset of cancer cells with the ability to break away from the original tumor site.

• Drugs that target specific cancer cells can lose effectiveness as the original mutations are lost.

Doctors are using this knowledge of tumor heterogeneity to prescribe combination therapies that attack multiple genetic and molecular targets.

Issels®: A Pioneer in Combination Therapies

Our individual immunotherapy programs are integrative, combining treatments that work together to form a comprehensive attack on cancer cells. Contact us to learn why Issels® is the right choice for powerful and non-toxic cancer treatment for patients in late and early stages.

October is National Breast Cancer Awareness Month

This Month is Breast Cancer Awareness Month. Support those Going Through Treatment Today!
This Month is Breast Cancer Awareness Month. Support those Going Through Treatment Today!

Nearly one in eight women in the United States will develop breast cancer, which has the highest death rate for females after lung cancer. Beginning in 1985, October has been designated as National Breast Cancer Awareness Month to educate the public and raise funds for research.

Raising Global Awareness of Breast Cancer

American Cancer Society and the pharmaceutical division of Imperial Chemical Industries, now known as Astra Zeneca, co-founded NBCAM to encourage women to get mammograms. Eight years later, Evelyn Lauder of Estee Lauder Companies established the Breast Cancer Research Foundation and popularized the symbolic pink ribbon.

NBCAM Activities

During the month of October, organizations around the world stage promotions and fundraisers to support NBCAM. Some of their major activities include:

• The National Football League integrates pink both on and off the field.

• Landmark buildings such as the White House and Tokyo Tower are lit up in pink.

• Race for the Cure, a series of 5K runs and fitness walks, originated in Dallas but is now held throughout the world.

• Susan G. Komen sponsors a three-day event where participants walk an average of 20 miles per day. 3-Day for the Cure® is held in major American cities such as Atlanta, Chicago and San Francisco.

• The third week of October is now dedicated to raising awareness of male breast cancer, which is less common but equally important.

Immunotherapy for Cancer: Treating Men and Women of All Ages

Both men and women diagnosed with breast cancer, leukemia and all other forms have been successfully treated with personally developed immunotherapy for cancer programs at Issels®. Contact us to learn more.